Table 4. Prognostic factors of relapse.
|
Univariate analysis
|
Multivariate analysis
|
|||
|---|---|---|---|---|
| Prognostic factors | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Chemotherapy | ||||
| FEC100 | 0.90 (0.61–1.19) | 0.47 | 0.91 (0.58–1.24) | 0.57 |
| Epi-Vnr | 1 | 1 | ||
| Tamoxifen | ||||
| No | 1.52 (1.21–1.83) | 0.009 | 1.34 (0.82–1.86) | 0.26 |
| Yes | 1 | 1 | ||
| Age (years) | ||||
| <40 | 1.58 (1.20–1.96) | 0.01 | 1.41 (0.91–1.91) | 0.17 |
| ⩾40 | 1 | 1 | ||
| Menopausal status | ||||
| Premenopausal | 1.48 (1.19–1.77) | 0.008 | 1.15 (0.63–1.67) | 0.59 |
| Postmenopausal | 1 | 1 | ||
| Surgery | ||||
| Tumorectomy | 0.76 (0.47–1.05) | 0.06 | 0.68 (0.32–1.04) | 0.04 |
| Mastectomy | 1 | 1 | ||
| SBR grade | 0.07 | 0.21 | ||
| 1 | 0.55 (0.00–1.23) | 0.56 (0.00–1.31) | ||
| 2 | 0.75 (0.43–1.07) | 0.79 (0.42–1.16) | ||
| 3 | 1 | 1 | ||
| Histological tumour size (mm) | ||||
| ⩽20 | 0.66 (0.34–0.98) | 0.01 | 0.68 (0.31–1.05) | 0.04 |
| >20 | 1 | 1 | ||
| Lymph node involvement | ||||
| 1–3 | 0.65 (0.29–0.99) | 0.02 | 0.84 (0.29–1.39) | 0.52 |
| >3 | 1 | 1 | ||
| HR status | ||||
| Negative | 0.89 (0.58–1.20) | 0.45 | 0.92 (0.47–1.37) | 0.73 |
| Positive | 1 | 1 | ||
95% CI=95% confidence interval; Epi-Vnr=epirubicin–vinorelbine; HR=hazard ratio; HR=hormone receptors; SBR=Scarff, Bloom and Richardson.